Basic studies and Phase I clinical trials have confirmed that combining PI3K and PARP inhibitors enhances drug sensitivity by inhibiting DNA homologous recombination repair mechanisms in ovarian cancer cells with PIK3 mutations or wild-type PIK3. Here, PIK3CG is linked to ovarian carcinoma.